7DPM

Crystal structure of SARS-CoV-2 Spike RBD in complex with MW06 Fab

Summary for 7DPM

• Entry DOI: 10.2210/pdb7dpm/pdb
• Descriptor: heavy chain of MW06, light chain of MW06, Spike protein S1, ... (6 entities in total)
• Functional Keywords: sars-cov-2, spike, rbd, antibody, ade, virus, immune system, immune system-viral protein complex, immune system/viral protein
• Biological source: Homo sapiens; More
• Total number of polymer chains: 12
• Total formula weight: 293040.53

Authors

Wang, J.,Jiao, S.,Wang, R.,Zhang, J.,Zhang, M.,Wang, M. (deposition date: 2020-12-20, release date: 2021-02-17, Last modification date: 2024-10-09)

Primary citation

Jiang, W.,Wang, J.,Jiao, S.,Gu, C.,Xu, W.,Chen, B.,Wang, R.,Chen, H.,Xie, Y.,Wang, A.,Li, G.,Zeng, D.,Zhang, J.,Zhang, M.,Wang, S.,Wang, M.,Gui, X.
Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
Mabs, 13:1953683-1953683, 2021

PubMed Abstract: The global pandemic of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in widespread social and economic disruption. Effective interventions are urgently needed for the prevention and treatment of COVID-19. Neutralizing monoclonal antibodies (mAbs) have demonstrated their prophylactic and therapeutic efficacy against SARS-CoV-2, and several have been granted authorization for emergency use. Here, we discover and characterize a fully human cross-reactive mAb, MW06, which binds to both SARS-CoV-2 and SARS-CoV spike receptor-binding domain (RBD) and disrupts their interaction with angiotensin-converting enzyme 2 (ACE2) receptors. Potential neutralization activity of MW06 was observed against both SARS-CoV-2 and SARS-CoV in different assays. The complex structure determination and epitope alignment of SARS-CoV-2 RBD/MW06 revealed that the epitope recognized by MW06 is highly conserved among SARS-related coronavirus strains, indicating the potential broad neutralization activity of MW06. In assays, no antibody-dependent enhancement (ADE) of SARS-CoV-2 infection was observed for MW06. In addition, MW06 recognizes a different epitope from MW05, which shows high neutralization activity and has been in a Phase 2 clinical trial, supporting the development of the cocktail of MW05 and MW06 to prevent against future escaping variants. MW06 alone and the cocktail show good effects in preventing escape mutations, including a series of variants of concern, B.1.1.7, P.1, B.1.351, and B.1.617.1. These findings suggest that MW06 recognizes a conserved epitope on SARS-CoV-2, which provides insights for the development of a universal antibody-based therapy against SARS-related coronavirus and emerging variant strains, and may be an effective anti-SARS-CoV-2 agent.

PubMed: 34313527
DOI: 10.1080/19420862.2021.1953683

Experimental method

X-RAY DIFFRACTION (3.304 Å)